iBio, Inc. Files 8-K Report

Ticker: IBIO · Form: 8-K · Filed: 2025-04-08T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory-disclosure

Related Tickers: IBIO

TL;DR

iBio filed an 8-K, mostly standard updates and exhibits.

AI Summary

On April 8, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific new material events or financial figures were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that iBio, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's operations or financial status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative or positive events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by iBio, Inc.?

The filing is a Current Report on Form 8-K, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits as of April 8, 2025.

When was this 8-K report filed by iBio, Inc.?

The report was filed as of April 8, 2025.

What is iBio, Inc.'s state of incorporation?

iBio, Inc. is incorporated in Delaware.

What is the principal executive office address for iBio, Inc.?

The principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

Does the filing mention any specific new business developments or financial results?

The provided excerpt of the 8-K filing does not detail specific new business developments or financial results, focusing on the report's nature and company identification.

From the Filing

0001420720-25-000018.txt : 20250408 0001420720-25-000018.hdr.sgml : 20250408 20250408073037 ACCESSION NUMBER: 0001420720-25-000018 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20250408 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250408 DATE AS OF CHANGE: 20250408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25820280 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250408x8k.htm 8-K iBio, Inc._April 8, 2025 0001420720 false 0001420720 2025-04-08 2025-04-08 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 8, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road, Suite 200 San Diego, California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO The Nasdaq Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ ​ Item 7.01. Regulation FD Disclosure. ​ iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. ​ The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the

View on Read The Filing